[Articles] Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies

Early use of intensive treatment with secukinumab in a treat-to-target strategy did not result in statistically superior outcomes compared with a conventional step-up treat-to-target approach. By month 12, both strategies led to similar clinical improvements, with half of patients attaining ACR50, suggesting that treatment targets can be met regardless of initial therapy.